Figitumumab + docetaxel in treatment of CRPC

Figitumumab (also known as CP-751,871) is a fully humanized monoclonal antibody designed to target the insulin-like growth factor type 1 receptor (IGF-IR). Data are now available from a very early-stage trial of figitumumab in combination with docetaxel in the treatment of patients with late-stage solid tumors — including castration-resiatant prostate cancer (CRPC). … READ MORE …